FDA Greenlights Novel T Cell Immunotherapy for Rare Soft-Tissue Cancer

U.S. regulators have approved an advanced therapy using T cells to combat a rare form of cancer originating in the body's soft tissues. This marks a significant extension of immunotherapy's capabilities to challenging sarcomas. 

The newly approved drug, Tecelra, developed by Adaptimmune Therapeutics, employs a method called T cell receptor therapy. While this approach is akin to CAR-T treatments that have revolutionized the management of certain blood cancers, Tecelra offers a distinct advantage: it is designed to target solid tumors, a challenge that CAR-T therapies have faced.

SOURCE: https://www.statnews.com/2024/08/02/fda-t-cell-immunotherapy-tcr-sarcoma-adaptimmune/ 

CREDITS: STAT NEWS